Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
START-or-NOT: Irbesartan after ICU acute kidney injury
2024-515845-40-00Phase 3Completed
- Sponsor
- Assistance publique - Hôpitaux de Paris
- Start
- Oct 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in acute kidney failure (AKF), chronic kidney disease (CKD) and cardiac morbidity comparing Irbesartan with Placebo (2 arms). Primary endpoint: Time to major adverse cardiovascular events (MACE). Started Oct 2024; status: completed.
02
Drugs
irbesartan
03
Conditions
acute kidney failure (AKF)chronic kidney disease (CKD)cardiac morbidity
Beyond the preview
Go deeper on 2024-515845-40-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-515845-40-00.